Back to trial detailsIntake questionnaire
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Applying to FirstHealth of the Carolinas · Pinehurst, North Carolina
Answer a few short questions to share with the research team.
0 of 3 answered